Vasudeva Reddy Nagavelli

Dr. Vasudeva Reddy Nagavelli


Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2016 in Bioorganic & Medicinal Chemistry Letters
Verified
Journal Article
Closed access
SNSirassu Narsimha
Sirassu Narsimha
NKNukala Satheesh Kumar
Nukala Satheesh Kumar
BSBattula Kumara Swamy
Battula Kumara Swamy
VNVasudeva Reddy Nagavelli
Vasudeva Reddy Nagavelli
SHS.K. Althaf Hussain
S.K. Althaf Hussain
MRM. Srinivasa Rao
M. Srinivasa Rao

29 January 2020 in Journal of Heterocyclic Chemistry
Verified
Journal Article
Closed access
PDF file
SNSirassu Narsimha
Sirassu Narsimha
SNSathesh Kumar Nukala
Sathesh Kumar Nukala
TJT. Savitha Jyostna
T. Savitha Jyostna
MRM. Ravinder
M. Ravinder
MRM. Srinivasa Rao
M. Srinivasa Rao
VNVasudeva Reddy Nagavelli
Vasudeva Reddy Nagavelli

22 July 2016 in RSC Advances
Verified
Journal Article
Closed access
PDF file
SNSirassu Narsimha
Sirassu Narsimha
KBKumara Swamy Battula
Kumara Swamy Battula
SNSatheesh Kumar Nukala
Satheesh Kumar Nukala
RGRamesh Gondru
Ramesh Gondru
YRYellu Narasimha Reddy
Yellu Narasimha Reddy
VNVasudeva Reddy Nagavelli
Vasudeva Reddy Nagavelli
A one pot strategy for the synthesis of fused benzoxazino[1,2,3]triazolyl[4,5-c]quinolinone derivatives 4a–4k via the reaction of 5-iodo-4-(prop-2-yn-1-yl)-2H-benzo[b][1,4]oxazin-3(4H)-one (3) with different aryl azides under copper and palladium catalysis in a ligand free condition is achieved. The reaction provided the desired fused triazoles in good to excellent yields. The synthesized derivatives were evaluated for their in vitro cytotoxic activity against MCF-7, A-549 and HeLa cancer cell lines using MTT assay. The cytotoxic activity results revealed that, compound 4d has shown a broad spectrum of activity against MCF-7 and A-549 with IC50 values of 11.18 ± 0.8 and 17.81 ± 0.6 μM, which are comparable to the standard drug, cisplatin. The remaining compounds have shown good to moderate activity against the tested cell lines. Based on the results obtained, a structure activity relationship (SAR) is discussed.

1 December 2018 in Chemistry of Heterocyclic Compounds
Verified
Journal Article
Closed access
PDF file
SNSirassu Narsimha
Sirassu Narsimha
KBKumara Swamy Battula
Kumara Swamy Battula
YRYellu Narasimha Reddy
Yellu Narasimha Reddy
VNVasudeva Reddy Nagavelli
Vasudeva Reddy Nagavelli

2 July 2016 in Medicinal Chemistry Research
Verified
Journal Article
Closed access
PDF file
VNVasudeva Reddy Nagavelli
Vasudeva Reddy Nagavelli
SNSatheesh Kumar Nukala
Satheesh Kumar Nukala
SNSirassu Narsimha
Sirassu Narsimha
KBKumara Swamy Battula
Kumara Swamy Battula
STSavitha Jyostna Tangeda
Savitha Jyostna Tangeda
YRYellu Narasimha Reddy
Yellu Narasimha Reddy

2 April 2018 in Synthetic Communications
Verified
Journal Article
Closed access
SNSirassu Narsimha
Sirassu Narsimha
KBKumara Swamy Battula
Kumara Swamy Battula
VNVasudeva Reddy Nagavelli
Vasudeva Reddy Nagavelli
A series of novel pyrimido[4,5-c]isoquinolines (3a–3h) and 1,2,3-triazole-coupled pyrimido[4,5-c]isoquinolines (4a–4h) were synthesized in good to excellent yields in the one-pot method. The reaction of 6-amino-1,3-dimethyluracil with different 2-iodo benzoyl chlorides using Pd catalyst in dimethylformamide afforded corresponding pyrimido[4,5-c]isoquinolines (3a–3h). One-pot reaction of pyrimido[4,5-c]isoquinolines with propargyl bromide and benzyl azide in THF at room temperature furnished 1,2,3-triazole-coupled pyrimido[4,5-c]isoquinoline (4a–4h). In vitro antioxidant activity examination revealed that compounds 4d and 4c found to exhibit potent antioxidant activity as compared to the standard drug Trolox with IC50 values 6.02 ± 0.6 and 12.18 ± 0.9 µM, respectively. GRAPHICAL ABSTRACT